comparemela.com

Latest Breaking News On - Director cyrus harmon - Page 5 : comparemela.com

Olema Pharmaceuticals, Inc (NASDAQ:OLMA) Director Sells $78,200 00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) Director Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $15.64, for a total transaction of $78,200.00. Following the transaction, the director now directly owns 943,714 shares of the […]

Brokerages Set Olema Pharmaceuticals, Inc (NASDAQ:OLMA) Price Target at $21 20

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have updated their coverage on the stock in […]

Olema Pharmaceuticals, Inc (NASDAQ:OLMA) Forecasted to Post FY2023 Earnings of ($2 46) Per Share

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) – Equities researchers at Lifesci Capital increased their FY2023 earnings estimates for Olema Pharmaceuticals in a note issued to investors on Monday, October 23rd. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($2.46) for the year, up from their prior […]

Olema Pharmaceuticals, Inc (NASDAQ:OLMA) Given Average Rating of Buy by Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have received an average recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in […]

Olema Pharmaceuticals, Inc (NASDAQ:OLMA) Receives $19 40 Consensus Target Price from Brokerages

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has earned a consensus recommendation of “Buy” from the six research firms that are covering the company, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued ratings on the stock in the last year […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.